Tibulizumab Skin Healing and Inflammation Evaluation for Lasting Defense

Summary

The study is a Phase 2, multi-center, randomized, double-blind, placebo-controlled study to evaluate the effects of tibulizumab over 16 weeks (Period 1) in adults with hidradenitis suppurativa, followed by a 16-week open-label extension period in which all participants will receive tibulizumab (Period 2)

Timeline

Start

2025-05-16

Primary completion

2026-11

Completion

2027-04

Drugs

Indications